Myasthenia gravis: vizsgálatok itt: Belgium
11 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleSafety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis
- Where
- Leuven
- Életkor
- 18 év and over
- People
- 59 worldwide
- Run by
- NMD Pharma A/S
See details and how to join2023-507539-40-00 - 3. fázisTaking peopleA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Where
- Anderlecht, Brugge, Gent, Leuven, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 199 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00 - 2. fázisTaking peopleADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Where
- Leuven, Liège
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- argenx
See details and how to joinNCT07673627 · EU 2025-522939-33-00 - 2/3. fázisCsak meghívásosEvaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
- Where
- Edegem, Gent
- Életkor
- 2 év to 18 év
- People
- 12 worldwide
- Run by
- argenx
See details and how to joinNCT05374590 · EU 2023-507379-23-00 - No phaseTaking peopleADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Where
- Leuven, Liège
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- argenx
See details and how to joinNCT07294170 - 3. fázisTaking peopleEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Where
- Leuven, Liège
- Életkor
- 18 év and over
- People
- 264 worldwide
- Run by
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00 - 2/3. fázisTaking peopleA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
- Where
- Gent
- Életkor
- 2 év to 17 év
- People
- 12 worldwide
- Run by
- argenx
See details and how to joinNCT06392386 · EU 2023-506159-12-00 - 2. fázisTaking peopleADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Where
- Leuven, Liège
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- argenx
See details and how to joinNCT07284420 · EU 2025-522492-28-00 - 2. fázisTaking peopleSafety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
- Where
- Leuven
- Életkor
- 18 év and over
- People
- 84 worldwide
- Run by
- NMD Pharma A/S
See details and how to joinNCT06414954 - No phaseTaking peopleA Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- Where
- Leuven
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- argenx
See details and how to joinNCT06298565 - No phaseTaking peopleGait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
- Where
- Liège
- Életkor
- 18 év and over
- People
- 300
- Run by
- Centre Hospitalier Universitaire de Liege
See details and how to joinNCT07136844